Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Mallinckrodt
Boehringer Ingelheim
Teva
Johnson and Johnson
Citi
QuintilesIMS
Chinese Patent Office

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RELISTOR

« Back to Dashboard

Clinical Trials for Relistor

Trial ID Title Status Sponsor Phase Summary
NCT00804141 Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation Completed Pfizer Phase 3 This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.
NCT00804141 Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation Completed Valeant Pharmaceuticals International, Inc. Phase 3 This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.
NCT00949377 Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department? Withdrawn Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation.
NCT00949377 Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department? Withdrawn Beth Israel Medical Center Phase 4 The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation.
NCT01004393 Methylnaltrexone for Opioid-induced Constipation in Cancer Patients Completed University of Vermont Phase 2 The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Relistor

Condition Name

Condition Name for Relistor
Intervention Trials
Constipation 4
Pharyngeal Dysfunction 2
Coronary Artery Disease 1
Opioid-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Relistor
Intervention Trials
Constipation 7
Emergencies 1
Critical Illness 1
Myocardial Ischemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Relistor

Trials by Country

Trials by Country for Relistor
Location Trials
United States 40
Canada 8
Korea, Republic of 3
Colombia 2
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Relistor
Location Trials
Florida 2
Pennsylvania 2
Minnesota 2
Michigan 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Relistor

Clinical Trial Phase

Clinical Trial Phase for Relistor
Clinical Trial Phase Trials
Phase 4 8
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Relistor
Clinical Trial Phase Trials
Completed 7
Withdrawn 2
Not yet recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Relistor

Sponsor Name

Sponsor Name for Relistor
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 4
Region Örebro County 2
Valeant Pharmaceuticals International, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Relistor
Sponsor Trials
Other 12
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Healthtrust
Chinese Patent Office
Dow
Covington
Chubb
Queensland Health
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.